Literature DB >> 1849279

Humanized antibodies for antiviral therapy.

M S Co1, M Deschamps, R J Whitley, C Queen.   

Abstract

Antibody therapy holds great promise for the treatment of cancer, autoimmune disorders, and viral infections. Murine monoclonal antibodies are relatively easy to produce but are severely restricted for therapeutic use by their immunogenicity in humans. Production of human monoclonal antibodies has been problematic. Humanized antibodies can be generated by introducing the six hypervariable regions from the heavy and light chains of a murine antibody into a human framework sequence and combining it with human constant regions. We humanized, with the aid of computer modeling, two murine monoclonal antibodies against herpes simplex virus gB and gD glycoproteins. The binding, virus neutralization, and cell protection results all indicate that both humanized antibodies have retained the binding activities and the biological properties of the murine monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849279      PMCID: PMC51341          DOI: 10.1073/pnas.88.7.2869

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  The effect of the temperature of incubation on the spread of Herpes simplex virus in an immune environment in cell culture.

Authors:  M D HOGGAN; B ROIZMAN; T B TURNER
Journal:  J Immunol       Date:  1960-02       Impact factor: 5.422

3.  Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

Authors:  G Hale; M J Dyer; M R Clark; J M Phillips; R Marcus; L Riechmann; G Winter; H Waldmann
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

4.  Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface.

Authors:  A O Fuller; P G Spear
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 5.  Infections with herpes simplex viruses (2).

Authors:  L Corey; P G Spear
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

6.  Studies on herpes simplex virus type 1 glycoproteins using monoclonal antibodies.

Authors:  J Koga; S Chatterjee; R J Whitley
Journal:  Virology       Date:  1986-06       Impact factor: 3.616

7.  Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion.

Authors:  W H Cai; B Gu; S Person
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease.

Authors:  J F Metcalf; J Koga; S Chatterjee; R J Whitley
Journal:  Curr Eye Res       Date:  1987-01       Impact factor: 2.424

9.  Protection against herpetic ocular disease by immunotherapy with monoclonal antibodies to herpes simplex virus glycoproteins.

Authors:  J F Metcalf; S Chatterjee; J Koga; R J Whitley
Journal:  Intervirology       Date:  1988       Impact factor: 1.763

10.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

View more
  23 in total

1.  Selecting open reading frames from DNA.

Authors:  Paola Zacchi; Daniele Sblattero; Fiorella Florian; Roberto Marzari; Andrew R M Bradbury
Journal:  Genome Res       Date:  2003-05       Impact factor: 9.043

2.  The human antibody library.

Authors:  S J Russell; M B Llewelyn; R E Hawkins
Journal:  BMJ       Date:  1992-03-07

3.  Critical contribution of VH-VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10.

Authors:  Takeshi Nakanishi; Kouhei Tsumoto; Akiko Yokota; Hidemasa Kondo; Izumi Kumagai
Journal:  Protein Sci       Date:  2008-02       Impact factor: 6.725

Review 4.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody.

Authors:  M E Verhoeyen; J A Saunders; M R Price; J D Marugg; S Briggs; E L Broderick; S J Eida; A T Mooren; R A Badley
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

6.  Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.

Authors:  Adalbert Krawczyk; Jürgen Krauss; Anna M Eis-Hübinger; Martin P Däumer; Robert Schwarzenbacher; Ulf Dittmer; Karl E Schneweis; Dirk Jäger; Michael Roggendorf; Michaela A E Arndt
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

Review 7.  From esoteric theory to therapeutic antibodies.

Authors:  T T Wu
Journal:  Appl Biochem Biotechnol       Date:  1994 May-Jun       Impact factor: 2.926

8.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

9.  Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro.

Authors:  R Burioni; R A Williamson; P P Sanna; F E Bloom; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

10.  Vectors for the expression of PCR-amplified immunoglobulin variable domains with human constant regions.

Authors:  M A Walls; K C Hsiao; L J Harris
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.